8-K: Nuo Therapeutics Changes Independent Auditor, Cites Material Weaknesses in Internal Controls

Nuo Therapeutics has dismissed Marcum LLP as its independent auditor and engaged MaloneBailey, LLP, citing material weaknesses in internal controls related to accounting and financial reporting resources.

Summary

• Nuo Therapeutics dismissed Marcum LLP as their independent registered public accounting firm, effective June 7, 2024.
• Marcum had been the company's auditor since September 27, 2017.
• The decision to change auditors was made by the Audit Committee of the Board of Directors.
• Marcum's audit reports for 2023 and 2022 did not contain adverse opinions or disclaimers, but included explanatory paragraphs regarding the company's ability to continue as a going concern.
• There were no disagreements between Nuo Therapeutics and Marcum on accounting principles, financial statement disclosure, or auditing scope.
• However, material weaknesses were identified in the company's internal controls related to insufficient accounting and financial reporting resources.
• Nuo Therapeutics has engaged MaloneBailey, LLP as their new independent auditor for the fiscal year ending December 31, 2024.
• MaloneBailey, LLP was not consulted on accounting principles or audit opinions prior to their engagement.

Sentiment

Score: 3

Explanation: The document highlights significant issues with internal controls and going concern, which are major negatives. The change in auditors adds uncertainty. Overall, the sentiment is negative.

Positives

• The company has taken action to address the material weaknesses by engaging a new auditor.
• There were no disagreements between the company and the previous auditor on accounting principles or auditing scope.

Negatives

• Material weaknesses were identified in the company's internal controls over financial reporting.
• The company lacked sufficient accounting and financial reporting resources.
• The previous auditor's reports included explanatory paragraphs about the company's ability to continue as a going concern.

Risks

• The identified material weaknesses in internal controls could lead to potential misstatements in financial reports.
• The company's ability to continue as a going concern has been questioned by the previous auditor.
• The change in auditors could introduce some uncertainty in the short term.

Future Outlook

The company will be working with MaloneBailey, LLP for the fiscal year ending December 31, 2024, and will need to address the identified material weaknesses in internal controls.

Management Comments

• The decision to change accountants was made by the Audit Committee of the Board of Directors of the Company.
• The Company identified material weaknesses in that it had not hired and did not maintain a sufficient complement of accounting and financial reporting resources.

Industry Context

Changes in auditors are not uncommon, but the identification of material weaknesses in internal controls is a concern that needs to be addressed. This change may be a result of increased scrutiny on financial reporting and internal controls in the current market environment.

Comparison to Industry Standards

• The identification of material weaknesses in internal controls is a significant issue that would be viewed negatively by investors and regulators.
• Companies are expected to maintain robust internal controls over financial reporting to ensure the accuracy and reliability of their financial statements.
• The fact that the previous auditor raised concerns about the company's ability to continue as a going concern is also a serious issue that needs to be addressed.
• Many companies of similar size and complexity to Nuo Therapeutics use larger, more established accounting firms, such as the Big Four (Deloitte, Ernst & Young, KPMG, and PwC), or other large national firms, which may have more resources and expertise in handling complex accounting issues.

Stakeholder Impact

• Shareholders may be concerned about the material weaknesses in internal controls and the going concern issue.
• Employees in the accounting and finance department may experience changes as the company addresses the identified weaknesses.
• Creditors may be more cautious about extending credit to the company given the going concern issue.

Next Steps

• The company will work with MaloneBailey, LLP on the audit for the fiscal year ending December 31, 2024.
• The company needs to address the identified material weaknesses in internal controls.

Key Dates

Keywords

auditor, accounting, internal controls, financial reporting, material weakness, Marcum LLP, MaloneBailey LLP